阿巴西普联合甲氨蝶呤治疗日本生物制剂初治活动性类风湿关节炎
这项IV期随机双盲安慰剂对照研究纳入日本生物制剂初治、ACPA阳性且存在早期骨侵蚀的活动性RA患者,比较阿巴西普+MTX与安慰剂+MTX的疗效与安全性。第16周阿巴西普组ACR20应答率75.4%,高于安慰剂组的27.7%(p<0.001);第24周vdH-mTSS平均变化分别为0.84与1.26(p=0.017)。安全性特征与既往观察一致。
要点
- 阿巴西普+MTX较单用MTX显著提高第16周ACR20应答率(75.4% vs 27.7%)。
- 第24周vdH-mTSS变化阿巴西普组0.84、安慰剂组1.26(p=0.017),提示抑制结构损伤进展。
- 安全性特征与既往观察一致,未报告新的安全信号。
核心结论
- 在ACPA阳性、有早期骨侵蚀且对MTX应答不足的日本生物制剂初治RA患者中,阿巴西普+MTX较单用MTX改善临床症状并抑制结构损伤进展。
研究设计与样本
- IV期多中心双盲随机安慰剂对照研究(NCT01758198),患者按1:1随机接受静脉阿巴西普(约10 mg/kg)或安慰剂,均联合MTX(≥6 mg/周)。
- 阿巴西普+MTX组203例、安慰剂+MTX组202例接受了治疗。
- 主要疗效目标为比较第16周ACR20应答率及第24周vdH-mTSS较基线的平均变化。
主要发现
- 第16周ACR20应答率阿巴西普组75.4%、安慰剂组27.7%(p<0.001)。
- 第24周vdH-mTSS较基线平均变化阿巴西普组0.84、安慰剂组1.26(p=0.017)。
- 影像学无进展率(vdH-mTSS变化≤最小可检测变化2.4)阿巴西普组88.1%、安慰剂组75.4%。
- 第16周DAS28(CRP)较基线调整平均变化阿巴西普组数值上大于安慰剂组。
- 截至第52周,DAS28(CRP)、SDAI、CDAI缓解比例阿巴西普组均高于安慰剂组。
关键数值与推荐
- ACR20应答率:第16周阿巴西普组75.4% vs 安慰剂组27.7%,p<0.001。
- vdH-mTSS较基线平均变化:第24周阿巴西普组0.84 vs 安慰剂组1.26,p=0.017。
- 影像学无进展判定阈值:vdH-mTSS变化≤最小可检测变化2.4;无进展率阿巴西普组88.1%、安慰剂组75.4%。
- 纳入人群条件:生物制剂初治、ACPA阳性、活动性RA伴早期骨侵蚀、对MTX应答不足的日本患者;MTX剂量≥6 mg/周。
临床怎么用
- 对生物制剂初治、ACPA阳性伴早期骨侵蚀且MTX应答不足的RA患者,可考虑阿巴西普+MTX以改善症状并延缓影像学进展。
- 用药期间安全性监测可参照既往阿巴西普已知安全性特征。
局限性
- 研究人群限定为日本生物制剂初治、ACPA阳性且伴早期骨侵蚀的RA患者,外推需谨慎。
- 摘要未报告其他亚组、长期结构结局及具体不良事件数据。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: To evaluate efficacy and safety of abatacept+methotrexate (MTX) in biologic-naive, anticitrullinated protein antibody (ACPA)-positive Japanese patients with active rheumatoid arthritis (RA) and early erosion versus placebo+MTX. METHODS: In this phase IV, multicentre, double-blind study (NCT01758198), patients were randomised (1:1) to receive intravenous abatacept (~10 mg/kg) or placebo, plus MTX (≥6 mg/week). Primary efficacy objectives were to compare American College of Rheumatology 20 (ACR20) response rates at week 16 and mean change from baseline in van der Heijde-modified total Sharp score (vdH-mTSS) at week 24 between abatacept+MTX and placebo+MTX groups. RESULTS: Overall, 203 and 202 patients received abatacept+MTX and placebo+MTX, respectively. At week 16, ACR20 response rates were higher in the abatacept (75.4%) versus placebo group (27.7%; p<0.001). Mean change from baseline in vdH-mTSS at week 24 was 0.84 in the abatacept and 1.26 in the placebo group (p=0.017). Radiographic non-progression rates (change in vdH-mTSS≤smallest detectable change (2.4)) were 88.1% and 75.4% in abatacept and placebo groups, respectively. Adjusted mean change from baseline in Disease Activity Score 28 (C-reactive protein) (DAS28 (CRP)) at week 16 demonstrated a numerically greater reduction in the abatacept versus placebo group. Proportions of patients with DAS28 (CRP), Simplified Disease Activity Index and Clinical Disease Activity Index remission up to week 52 were higher in the abatacept versus placebo group. The abatacept safety profile was consistent with previous observations. CONCLUSIONS: Compared with MTX alone, abatacept+MTX improved clinical symptoms and inhibited structural damage progression in ACPA-positive, Japanese patients with RA, early erosion and inadequate response to MTX.
引用
- Matsubara T, Inoue H, Nakajima T, et al. Abatacept in combination with methotrexate in Japanese biologic-naive patients with active rheumatoid arthritis: a randomised placebo-controlled phase IV study. RMD Open. 2018. PMID: 30622737. doi:10.1136/rmdopen-2018-000813
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。